PT - JOURNAL ARTICLE AU - Max T. Aung AU - Kelly M. Bakulski AU - Jason I. Feinberg AU - John F. Dou AU - John D. Meeker AU - Bhramar Mukherjee AU - Rita Loch-Caruso AU - Christine Ladd-Acosta AU - Heather E. Volk AU - Lisa A. Croen AU - Irva Hertz-Picciotto AU - Craig J. Newschaffer AU - M. Daniele Fallin TI - Maternal blood metal concentrations and whole blood DNA methylation during pregnancy in the Early Autism Risk Longitudinal Investigation (EARLI) AID - 10.1101/2020.05.29.20116384 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.29.20116384 4099 - http://medrxiv.org/content/early/2020/06/16/2020.05.29.20116384.short 4100 - http://medrxiv.org/content/early/2020/06/16/2020.05.29.20116384.full AB - Background Metals exposures have important health effects in pregnancy. The maternal epigenome may be responsive to these exposures. We tested whether metals are associated with concurrent differential maternal whole blood DNA methylation.Methods In the Early Autism Risk Longitudinal Investigation (EARLI) cohort, we measured first or second trimester maternal blood metals concentrations (cadmium, lead, mercury, manganese, and selenium) in 215 participants using inductively coupled plasma mass spectrometry. DNA methylation in maternal whole blood was measured in the same specimens on the Illumina 450K array (201 participants). A subset sample of 97 women had both measures available for analysis, all of whom did not report smoking during pregnancy. Linear regression was used to test for site-specific associations between individual metals and DNA methylation, adjusting for cell type composition and confounding variables. Discovery gene ontology analysis was conducted on the top 1,000 sites associated with each metal to elucidate downstream pathways.Results In multiple linear regression, we observed hypermethylation at 11 DNA methylation sites associated with lead (FDR q-value <0.1), near the genes CYP24A1, ASCL2, FAT1, SNX31, NKX6-2, LRC4C, BMP7, HOXC11, PCDH7, ZSCAN18, and VIPR2. Lead associated sites were enriched (FDR q-value <0.1) for the pathways cell adhesion, nervous system development, and calcium ion binding. Manganese was associated with hypermethylation at four DNA methylation sites (FDR q-value <0.1), one of which was near the gene ARID2. Manganese associated sites were enriched for cellular metabolism pathways (FDR q-value<0.1). Effect estimates for DNA methylation sites associated (p<0.05) with cadmium, lead, and manganese were highly correlated (Pearson ρ >0.86).Discussion Single DNA methylation sites associated with lead and manganese may be potential biomarkers of exposure or implicate downstream gene pathways. Future studies should replicate our findings to characterize potential toxicological mechanisms of trace metals through the maternal epigenome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health (grants R01ES016443, R01ES017646, R01ES025531, R01ES025574, P30ES017885, R01AG055406). Support for Max Aung was provided in part by a grant from the Robert Wood Johnson Foundation Health Policy Research Scholars program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards (IRB) at organizations in the four study sites (Drexel University, Johns Hopkins University, University of California, Davis, and Kaiser Permanente Research) approved the EARLI study. The University of Michigan IRB also approved additional sample analyses.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this study are not available for public use to protect human subjects.